Business Standard

S&P lowers outlook for Jubilant Pharma to negative, sees weak performance

Operating performance may remain weak due to regulatory issues, says rating agency.

Photo: Bloomberg
Premium

Photo: Bloomberg

Abhijit Lele Mumbai
Standard and Poor’s (S&P) has lowered outlook on Jubilant Pharma Ltd from “stable” to “negative” on likely weaker operating performance by the drugmaker.

The rating agency affirmed the long-term issuer credit rating at “BB”. Jubilant’s operating performance could remain weak over the next 12 months due to regulatory issues in its generics business and the loss of one-time development and manufacturing contracts related to Covid-19.

The negative outlook reflects the likelihood of a downgrade if the group's EBITDA margins remain below 20 per cent and debt-to-EBITDA ratio stays above 2x without signs of improving toward about 2x beyond the next

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Mar 30 2022 | 12:23 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com